Professor of Medicine, Haas Chair in Genetics, Chief, Molecular Hematology and Therapy, U.T. MD Anderson Cancer Center
Hematology
Dr. Michael Andreeff, MD
|
|
Give Review
Dr. Michael Andreeff practices Hematology. Michael Andreeff, MD is a published doctor. He published 62 publications, including: 'Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFB/IL1 signaling network.' Michael Andreeff is registered with Medicare and accepts Medicare payments.
Publications
- Anti-apoptotic ARC protein confers chemoresistance by controlling Leukemia-microenvironment interactions through a NFκB/IL1β signaling network.
- Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.
- Results of the Phase 1 Trial of RG7112, a Small-molecule MDM2 Antagonist in Leukemia.
- Improvement in clinical outcome of FLT3 ITD mutated Acute myeloid leukemia patients over the last one and a half decade.
- Single-Cell mass cytometry reveals intraCellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor Cells.
- Enforced fucosylation of cord blood hematopoietic Cells accelerates neutrophil and platelet engraftment after transplantation.
- Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed Acute myeloid leukemia and Acute lymphoblastic leukemia.
- Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ Acute lymphoblastic leukemia.
- The effect of calcium channel blockers on the outcome of Acute myeloid leukemia.
- Phase I/II Trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with Acute myeloid leukemia and myelodysplastic syndrome.
- Prevention of murine lupus nephritis by targeting multiple signaling axes and oxidative stress using a synthetic triterpenoid.
- Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced Cell death through BIRC2/MAP3K14 signa...
- Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of Acute myeloid leukemia.
- SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase Chronic myeloid...
- The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in Acute myeloid leukemia cells.
- Treatment with FLT3 inhibitor in patients with FLT3-mutated Acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
- Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myeloid Leukemia Cells.
- Implications of the miR-10 family in chemotherapy response of NPM1 mutated AML.
- Reciprocal Leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.
- Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102.
- Reversal of Acquired Drug Resistance in FLT3-mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies.
- Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with Acute myeloid leukemia.
- Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents.
- Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia.
- Selective BCL-2 Inhibition by ABT-199 Causes On Target Cell Death in Acute Myeloid Leukemia.
- Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML.
- BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia.
- BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor Cells.
- Targeting connective tissue growth factor (CTGF) in Acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth.
- CXC Chemokine Receptor 4 Expression, CXC Chemokine Receptor 4 Activation, and Wild-Type Nucleophosmin Are Independently Associated With Unfavorable Prognosis in Patien...
- Mesenchymal CD44 Expression Contributes to the Acquisition of an Activated Fibroblast Phenotype via TWIST Activation in the Tumor Microenvironment.
- Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates Leukemia bone marrow engraftment.
- Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤ 60 years with newly diagnosed Acute myeloid leukemia (AML).
- HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced Leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in ...
- XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML Cells.
- Phase II study of azacytidine plus sorafenib in patients with Acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
- Cell-Surface Expression of Neuron-Glial Antigen 2 (NG2) and Melanoma Cell Adhesion Molecule (CD146) in Heterogeneous Cultures of Marrow-Derived Mesenchymal Stem Cells.
- Prognostic impact and targeting of CRM1 in Acute myeloid leukemia.
- TGF-? Mediates Homing of Bone Marrow-Derived Human Mesenchymal Stem Cells to Glioma Stem Cells.
- The CXCR4 Antagonist AMD3465 Regulates Oncogenic Signaling and Invasiveness In Vitro and Prevents Breast Cancer Growth and Metastasis In Vivo.
- Tumor stroma engraftment of gene-modified mesenchymal stem Cells as anti-tumor therapy against ovarian cancer.
- Molecular characterization of de novo Philadelphia chromosome-positive Acute myeloid leukemia.
- Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in Acute myelogenous leukemia cells.
- Regulation of HIF-1α signaling and chemoresistance in Acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment.
- Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML under conditions mimicking the bone marrow microenvironment.
- Laser nanothermolysis of human Leukemia cells using functionalized plasmonic nanoparticles.
- Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of Acute lymphoblastic leukemia cells.
- A Randomized Controlled Trial of an Intensive Insulin Regimen in Patients With Hyperglycemic Acute Lymphoblastic Leukemia.
- Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment.
- MEK inhibition enhances ABT-737-induced Leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
- Activation of apoptosis signaling eliminates CD34(+) progenitor Cells in blast crisis CML independent of response to tyrosine kinase inhibitors.
- Targeting the Leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
- Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell Lymphoma.
- CXCR4 expression and biologic activity in Acute myeloid leukemia are dependent on oxygen partial pressure.
- Functional proteomic profiling of AML predicts response and survival.
- HOX expression patterns identify a common signature for favorable AML.
- ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.
- Proteomic Profiling Identifies Distinct Protein Patterns in Acute Myelogenous Leukemia CD34+CD38- Stem-Like Cells.
- TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
- Mitochondrial uncoupling and the reprograming of intermediary metabolism in Leukemia cells.
- Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML Cells.
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Burkitt's Lymphoma
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Education
-
University of Heidelberg Faculty of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1437263506 | |
| NPPES Provider LastName | ANDREEFF | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 122.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1437263506 |
| Last Name Of The Provider | ANDREEFF |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
Dr. Muffaddal S. Morkas, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Craig A. Kovitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Monisha Singh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tejash R. Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Joel W. Abramowitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mario Cervantes-Vazquez, MD |
|
|
Dr. Robert C. Bast Jr., MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Qaiser Bashir, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ellen J. Schlette, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Caroline C. Waddell, MD |
|
|
Dr. Charles Lu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jun Zhang, MD |
|
|
Dr. Shahab A. Khan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark A. Lewis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joe L. Moake, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Tara N. Miller, MD |
|
|
Dr. Patricio Salvador, MD |
|
|
Dr. Maria F. Benton, MD
This Doctor is OpenDoctor Recommended.
|